This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag. This protein contains a furin-like convertase cleavage site, 355-RQYR-358, and will be partially processed into N and C-terminal fragment with calculated MW of 38.1 kDa and 26.4 kDa respectively. The protein migrates as 40 kDa and 70-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>85% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human Glypican 3, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 85%.
Immobilized Human FGF basic, Tag Free (Cat. No. BFF-H4117) at 2 μg/mL (100 μL/well) can bind Biotinylated Human Glypican 3, His,Avitag (Cat. No. GP3-H82E5) with a linear range of 1-16 ng/mL (QC tested).
293 cells were transfected with anti-GPC3-scFv and RFP tag. 2e5 of the cells were first stained with B. Biotinylated Human Glypican 3, His,Avitag (Cat. No. GP3-H82E5, 10 μg/mL) and C. biotinylated protein control, followed by FITC-conjugated streptavidin. A. Non-transfected 293 cells and C. biotinylated protein control were used as negative control. RFP was used to evaluate CAR (anti-GPC3-scFv) expression and FITC was used to evaluate the binding activity of Biotinylated Human Glypican 3, His,Avitag (Cat. No. GP3-H82E5).
Authors: Berman RM, et al
Journal: Cancer Biother Radiopharm 43696
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.